Number of pages: 100 | Report Format: PDF | Published date: 13 October, 2022
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
According to the deep-dive market assessment study by Growth+ Reports, the global acute myeloid leukemia market was valued at US$ 1.8 billion in 2021. The market is expected to witness a CAGR of 10.2% from 2022 to 2030.
Market Fundamentals
Acute myeloid leukemia (AML) is a type of hematologic cancer distinguished by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and other tissues. AML is caused by a series of genetic changes in a hematopoietic precursor cell. Leukemic cells proliferate in the bone marrow and interfere with normal blood cell production, resulting in weakness, infection, bleeding, and other symptoms and complications. While recurrent acquired genetic abnormalities have been discovered in leukemia blasts, most patients' direct causes of AML are unknown.
[4634534]
Market Dynamics
The rising incidence rate of acute myeloid leukemia and the increased death rate among patients globally are the major driving factors of the global acute myeloid leukemia market. Moreover, the growing geriatric population is increasing the patient pool for acute myeloid leukemia. The increased advancement in pharmacology and molecular biology to promote drug development is also propelling the growth in the global market. Additionally, the government and non-government organizations taking initiatives to create awareness regarding early diagnosis and treatment of different cancer are also increasing the demand for acute myeloid leukemia treatment. Similarly, the rise in the research related to targeted therapies and biologics is also playing a pivotal role in the growth of the global acute myeloid leukemia market. The rise in unhealthy lifestyles, such as tobacco smoking and alcohol consumption, is also increasing the patient pool for acute myeloid leukemia.
Furthermore, with increased investment in research and development, more clinical trials are being conducted to demonstrate the efficacy of the drugs, which is also expected to boost the global acute myeloid leukemia market. However, the high cost of acute myeloid leukemia treatment products such as biologics, chemotherapy, and targeted therapies is the major restricting factor of the global acute myeloid leukemia market. Moreover, the lack of skilled professionals and awareness in developing countries is also hindering market growth.
Market Ecosystem
The global acute myeloid leukemia market has been analyzed from two perspectives: drug class, and region.
Acute Myeloid Leukemia Market by Drug Class
[78667554]
Based on drug class, the global acute myeloid leukemia market is segmented into antineoplastics, kinase inhibitors, hedgehog pathway inhibitors, and others (including combinations). The antineoplastics segment dominates the global acute myeloid leukemia market with the largest market share in 2021. The large share of the antineoplastics segment can largely be attributed to the excellent demand for antineoplastics drugs as it is the most commonly used drug for cancer. Moreover, the overall survival rate of people who are treated with antineoplastics is thus increasing the demand for antineoplastics drugs. Additionally, these drugs are used as primary treatment for most cancers. According to the National Cancer Institute’s SEER*RX database, more than 2000 antineoplastic drugs exist. Similarly, rising Cytarabine approvals by the US Food and Drug Administration for treating acute myeloid leukemia are also expected to drive the segment growth.
Acute Myeloid Leukemia Market by Region
Based on region, the global acute myeloid leukemia market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America dominated the global acute myeloid leukemia market in 2021, followed by Europe. Asia Pacific market is anticipated to grow at the fastest CAGR during the forecast period. The large share of North America can largely be attributed to the rising prevalence of acute myeloid leukemia. According to the American Society of Clinical Oncology, in 2021, an estimated 20,240 people of all ages (11,230 men and boys and 9,010 women and girls) will be diagnosed with this disease in the United States. Acute myeloid leukemia is the second most common type of leukemia in both adults and children, with adults accounting for the vast majority of cases. Furthermore, increasing research & development and product launches for acute myeloid leukemia are boosting the market growth in this region. The presence of well-developed healthcare infrastructure and the top market players in the region is also expected to propel regional growth.
Competitive Landscape
The prominent players operating in the global acute myeloid leukemia market are:
Strategic Developments
Report Attribute |
Details |
Market size value in 2021 |
US$ 1.8 billion |
Revenue forecast in 2030 |
US$ 4.31 billion |
Growth Rate |
CAGR of 10.2% from 2022 to 2030 |
Base year for estimation |
2021 |
Forecast period |
2022-2030 |
Segments covered |
Drug class, and region. |
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
The North America region dominates in market share. However, the Asia Pacific Region has the fastest growth rate and can be considered the key growth region.
• The prominent players operating in the global acute myeloid leukemia market are Pfizer Inc., Genentech Inc., Novartis AG, Astellas Pharma Inc., Bristol-Myers Squibb Company, Servier Laboratories, Jazz Pharmaceuticals plc, Celgene Corporation, AROG Pharmaceuticals, Astex Pharmaceuticals, Actinium Pharmaceuticals, GlycoMimetics, Rafael Pharmaceuticals, F. Hoffmann-La Roche Ltd., Takeda Oncology, Helsinn Healthcare, Tolero Pharmaceuticals, and Syros Pharmaceuticals among others.
The estimated market size of the acute myeloid leukemia market in 2030 is expected to be US$ 4.31 billion.
The CAGR of the global acute myeloid leukemia market is 10.2% in the forecast period of 2022 to 2030.
The antineoplastics segment dominates the global acute myeloid leukemia market.
*Insights on financial performance is subject to availability of information in public domain
Growth+Reports can now be customized as per client’s needs through GRG Health’s primary research and knowledge services capabilities
GRG Health’s unique GrowthMIX approach and robust research methodology helps us deliver unique & meaningful insights to our clients and uncover trends that won’t meet the standard approach